BACKGROUND: Glucagon-like peptide 1 (GLP-1) is a gut hormone which acts as an incretin and is therefore of major interest in treatment of type II diabetes mellitus. GLP-1 circulates in many different forms, some of which are biologically active and others are not. Our hypothesis was that various methods to measure GLP-1 detect different forms of GLP-1, which may cause confusion when comparing results. METHODS: We compared three assays, the GLP-1 (active) ELISA (Linco research; ELISA(LINCO)), GLP-1 (total) RIA (Linco research; RIA(LINCO)) and the total GLP-1 RIA developed by the group of Holst (RIA(HOLST)) on specimens obtained during meal studies. In addition, we studied the effect of addition of a DPP-4 inhibitor. RESULTS: The correlation between RIA(LINCO) and ELISA(LINCO) was highest (r=0.76; n=35; p<0.01), whereas results of RIA(HOLST) correlated less with those of RIA(LINCO) and ELISA(LINCO) (r=0.35 and 0.39 respectively; n=35; p<0.05). GLP-1 results measured with ELISA(LINCO) were higher (median 28%; p<0.001) upon addition of the DPP-4 inhibitor. CONCLUSION: Two commercially available GLP-1 assays do not necessarily give results equal to the well-defined GLP-1 assay developed in Copenhagen. Absolute values are also different due to differences in standardisation. Moreover, assays detect different forms of GLP-1, which hampers comparison to published data.
BACKGROUND:Glucagon-like peptide 1 (GLP-1) is a gut hormone which acts as an incretin and is therefore of major interest in treatment of type II diabetes mellitus. GLP-1 circulates in many different forms, some of which are biologically active and others are not. Our hypothesis was that various methods to measure GLP-1 detect different forms of GLP-1, which may cause confusion when comparing results. METHODS: We compared three assays, the GLP-1 (active) ELISA (Linco research; ELISA(LINCO)), GLP-1 (total) RIA (Linco research; RIA(LINCO)) and the total GLP-1 RIA developed by the group of Holst (RIA(HOLST)) on specimens obtained during meal studies. In addition, we studied the effect of addition of a DPP-4 inhibitor. RESULTS: The correlation between RIA(LINCO) and ELISA(LINCO) was highest (r=0.76; n=35; p<0.01), whereas results of RIA(HOLST) correlated less with those of RIA(LINCO) and ELISA(LINCO) (r=0.35 and 0.39 respectively; n=35; p<0.05). GLP-1 results measured with ELISA(LINCO) were higher (median 28%; p<0.001) upon addition of the DPP-4 inhibitor. CONCLUSION: Two commercially available GLP-1 assays do not necessarily give results equal to the well-defined GLP-1 assay developed in Copenhagen. Absolute values are also different due to differences in standardisation. Moreover, assays detect different forms of GLP-1, which hampers comparison to published data.
Authors: A Basolo; S Heinitz; E J Stinson; B Begaye; M Hohenadel; P Piaggi; J Krakoff; S B Votruba Journal: J Endocrinol Invest Date: 2018-10-03 Impact factor: 4.256
Authors: Sara F Michaliszyn; SoJung Lee; Fida Bacha; Hala Tfayli; Lama Farchoukh; Andrea Mari; Ele Ferrannini; Silva Arslanian Journal: Pediatr Diabetes Date: 2016-01-22 Impact factor: 4.866
Authors: Elizabeth Adams; Pauline Genter; Emma Keefe; Kevin Sandow; Virginia Gray; Jerome I Rotter; Yii-Der Ida Chen; Eli Ipp Journal: Diabetes Res Clin Pract Date: 2017-11-16 Impact factor: 5.602
Authors: Sophie J Bernelot Moens; Hans L Mooij; H Carlijne Hassing; Janine K Kruit; Julia J Witjes; Michiel A J van de Sande; Aart J Nederveen; Ding Xu; Geesje M Dallinga-Thie; Jeffrey D Esko; Erik S G Stroes; Max Nieuwdorp Journal: PLoS One Date: 2014-12-26 Impact factor: 3.240
Authors: M Yanina Pepino; Courtney D Tiemann; Bruce W Patterson; Burton M Wice; Samuel Klein Journal: Diabetes Care Date: 2013-04-30 Impact factor: 19.112